[A22-66] Palbociclib (breast cancer) – Benefit assessment according to § 35a SGB V
Last updated 15.12.2022
Project no.:
A22-66
Commission:
Commission awarded on 01.07.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Postmenopausal patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in first-line therapy
Proof of lesser benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-63 | Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A16-74 | Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-120 | Palbociclib (breast cancer, combination with an aromatase inhibitor) – Addendum to Commission A22-66 | Commission completed |
Federal Joint Committee (G-BA)
2022-12-15 A G-BA decision was published.
G-BA documents on this decision